Prenylterphenyllin, a regulator of P53, inhibits colorectal cancer progression through oxidative stress and energy metabolism pathway
Redox Biology · 2026-03 · 90 · 103993
DOI: 10.1016/j.redox.2025.103993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Redox Biology, 2026-03. Verfasst von Yuhan Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Southeast University, Nanjing, 210009, China; School of Traditional Chinese Materia Medica, Shenyang Ph…. Hauptthemen laut MEDLINE: Oxidative Stress, Tumor Suppressor Protein p53, Energy Metabolism, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangsu Provincial Key Research and Development Program, National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Colorectal cancer (CRC) is one of the most prevalent and deadly cancers globally, with poor prognosis primarily due to metastasis and resistance to conventional therapies. This study evaluated the antitumor potential of prenylterphenyllin, a natural product derived from Aspergillus candidus. Prenylterphenyllin significantly reduced CRC cells viability and migration, while promoting apoptosis and cell-cycle arrest. Transcriptomic analysis showed activation of the p53 signaling pathway and inhibition of cell-cycle-related genes. Prenylterphenyllin also disrupted mitochondrial function and oxidative phosphorylation, increasing oxidative stress. In vivo, it suppressed tumor growth and lung metastasis without notable toxicity. These results highlight that prenylterphenyllin is a promising candidate for CRC therapy, capable of inhibiting tumor growth, migration, and metastasis while inducing apoptosis through the modulation of energy metabolism and oxidative stress. As a promising candidate, prenylterphenyllin may offer new therapeutic opportunities for CRC, particularly for metastatic disease. Collectively, this study identifies prenylterphenyllin as a novel therapeutic candidate for CRC and illuminates its promising therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing, 210009, China; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China; Department of Immuno…
- Department of Immunology, School of Basic Medical Sciences, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, N…
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing, 210009, China; Department of Immunology, School of Basic Medical Sciences, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Col…
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: xj110121@126.com.
- Department of Gastroenterology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu Province, 214023, China. Electr…
- Department of Clinical Laboratory, Kunshan Hospital of Chinese Medicine, Affiliated Hospital of Yangzhou University, Kunshan, Jiangsu, China. Electronic address: chunyanhe530@163.com.
Förderung
- Jiangsu Provincial Key Research and Development Program
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- China Postdoctoral Science Foundation
Zitieren
APA
Zhang, Y., Han, Y., Li, S., Shan, R., Lin, L., Gu, Z., Wang, R., Chen, Y., Xiao, J., An, F., Hu, C., & He, C. (2026). Prenylterphenyllin, a regulator of P53, inhibits colorectal cancer progression through oxidative stress and energy metabolism pathway. Redox Biology, 90, 103993. https://doi.org/10.1016/j.redox.2025.103993
Vancouver
Zhang Y, Han Y, Li S, Shan R, Lin L, Gu Z, et al. Prenylterphenyllin, a regulator of P53, inhibits colorectal cancer progression through oxidative stress and energy metabolism pathway. Redox Biology. 2026;90:103993. doi:10.1016/j.redox.2025.103993
BibTeX
@article{Zhang2026,
author = {Zhang, Yuhan and Han, Yueqing and Li, Songmao and Shan, Ruimin and Lin, Ling and Gu, Zhengyu and Wang, Ruiyu and Chen, Yun and Xiao, Jiao and An, Fangmei and Hu, Chupeng and He, Chunyan},
title = {Prenylterphenyllin, a regulator of P53, inhibits colorectal cancer progression through oxidative stress and energy metabolism pathway},
journal = {Redox Biology},
year = {2026},
volume = {90},
pages = {103993},
doi = {10.1016/j.redox.2025.103993}
}
EUVIMED